These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 17971529)

  • 1. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.
    Reddy PS; Burroughs KD; Hales LM; Ganesh S; Jones BH; Idamakanti N; Hay C; Li SS; Skele KL; Vasko AJ; Yang J; Watkins DN; Rudin CM; Hallenbeck PL
    J Natl Cancer Inst; 2007 Nov; 99(21):1623-33. PubMed ID: 17971529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.
    Rudin CM; Poirier JT; Senzer NN; Stephenson J; Loesch D; Burroughs KD; Reddy PS; Hann CL; Hallenbeck PL
    Clin Cancer Res; 2011 Feb; 17(4):888-95. PubMed ID: 21304001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001.
    Poirier JT; Reddy PS; Idamakanti N; Li SS; Stump KL; Burroughs KD; Hallenbeck PL; Rudin CM
    J Gen Virol; 2012 Dec; 93(Pt 12):2606-2613. PubMed ID: 22971818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.
    Liu Z; Zhao X; Mao H; Baxter PA; Huang Y; Yu L; Wadhwa L; Su JM; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Hurwitz RL; Lau CC; Chintagumpala M; Blaney SM; Li XN
    Neuro Oncol; 2013 Sep; 15(9):1173-85. PubMed ID: 23658322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.
    Poirier JT; Dobromilskaya I; Moriarty WF; Peacock CD; Hann CL; Rudin CM
    J Natl Cancer Inst; 2013 Jul; 105(14):1059-65. PubMed ID: 23739064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Structure-Guided Genetic Modification Strategy: Developing Seneca Valley Virus Therapy against Nonsensitive Nonsmall Cell Lung Carcinoma.
    Zhao Z; Cao L; Sun Z; Liu W; Li X; Fang K; Shang X; Hu J; Chen H; Lou Z; Qian P
    J Virol; 2023 May; 97(5):e0045923. PubMed ID: 37097154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.
    Yu L; Baxter PA; Zhao X; Liu Z; Wadhwa L; Zhang Y; Su JM; Tan X; Yang J; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Blaney SM; Chintagumpala M; Hurwitz RL; Li XN
    Neuro Oncol; 2011 Jan; 13(1):14-27. PubMed ID: 21075780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus.
    Wadhwa L; Hurwitz MY; Chévez-Barrios P; Hurwitz RL
    Cancer Res; 2007 Nov; 67(22):10653-6. PubMed ID: 18006805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.
    Miles LA; Burga LN; Gardner EE; Bostina M; Poirier JT; Rudin CM
    J Clin Invest; 2017 Aug; 127(8):2957-2967. PubMed ID: 28650343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Seneca Valley Virus: past perspectives and future directions.
    Burke MJ
    Oncolytic Virother; 2016; 5():81-9. PubMed ID: 27660749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus.
    Venkataraman S; Reddy SP; Loo J; Idamakanti N; Hallenbeck PL; Reddy VS
    Structure; 2008 Oct; 16(10):1555-61. PubMed ID: 18940610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma.
    Miyamoto S; Inoue H; Nakamura T; Yamada M; Sakamoto C; Urata Y; Okazaki T; Marumoto T; Takahashi A; Takayama K; Nakanishi Y; Shimizu H; Tani K
    Cancer Res; 2012 May; 72(10):2609-21. PubMed ID: 22461509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
    Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors.
    Lun X; Ruan Y; Jayanthan A; Liu DJ; Singh A; Trippett T; Bell J; Forsyth P; Johnston RN; Narendran A
    Mol Oncol; 2013 Oct; 7(5):944-54. PubMed ID: 23816608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.
    Morton CL; Houghton PJ; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2010 Aug; 55(2):295-303. PubMed ID: 20582972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Assessment of the Health Risk for Livestock When Animal Viruses Are Applied in Human Oncolytic Therapy: A Case Study for Seneca Valley Virus.
    Schijven J; Brizee S; Teunis P; de Vos C; Eblé P; Rutjes S
    Risk Anal; 2019 May; 39(5):982-991. PubMed ID: 30395685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
    Fu X; Nakamori M; Tao L; Amato R; Zhang X
    Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
    Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
    J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seneca Valley Virus Suppresses Host Type I Interferon Production by Targeting Adaptor Proteins MAVS, TRIF, and TANK for Cleavage.
    Qian S; Fan W; Liu T; Wu M; Zhang H; Cui X; Zhou Y; Hu J; Wei S; Chen H; Li X; Qian P
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28566380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
    Kanai R; Eguchi K; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
    J Gene Med; 2006 Nov; 8(11):1329-40. PubMed ID: 16955534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.